tiprankstipranks
Trending News
More News >
Daré Bioscience Inc (DARE)
NASDAQ:DARE
Advertisement

Daré Bioscience (DARE) AI Stock Analysis

Compare
1,855 Followers

Top Page

DARE

Daré Bioscience

(NASDAQ:DARE)

Rating:50Neutral
Price Target:
$2.50
▼(-6.02%Downside)
Daré Bioscience's overall stock score is primarily impacted by its challenging financial situation, including negative equity and ongoing losses. However, positive developments in clinical trials and strategic initiatives offer a glimpse of potential future improvement.
Positive Factors
Product Development
Positive interim results from the P3 study of Ovaprene show a pregnancy rate in line with or better than current contraceptive methods.
Strategic Partnerships
If Bayer exercises its commercial option for Ovaprene, Dare would earn another $20M milestone, strengthening the company's balance sheet.
Negative Factors
Financial Needs
Additional capital will likely be needed, and potentially significantly dilutive, to fund Daré's programs.
Study Enrollment
Enrollment in the study was negatively affected by NIH cuts, causing recruitment at NIH CCTN sites to pause.

Daré Bioscience (DARE) vs. SPDR S&P 500 ETF (SPY)

Daré Bioscience Business Overview & Revenue Model

Company DescriptionDaré Bioscience (DARE) is a biopharmaceutical company focusing on the development and commercialization of innovative products in women's health. The company's portfolio includes a range of clinical-stage candidates designed to address unmet needs in contraception, fertility, and sexual health. Daré Bioscience aims to enhance the quality of life for women by developing products that offer novel or improved therapeutic options across these key areas.
How the Company Makes MoneyDaré Bioscience makes money primarily through the development and commercialization of its proprietary women's health products. The company generates revenue by partnering with pharmaceutical companies for the commercialization and distribution of its products once approved by regulatory authorities. These partnerships often include upfront payments, milestone payments based on the achievement of development and regulatory milestones, and royalties from product sales. Daré Bioscience's earnings are also supported by government grants and research collaborations that help fund the development of its clinical pipeline.

Daré Bioscience Earnings Call Summary

Earnings Call Date:May 13, 2025
(Q1-2025)
|
% Change Since: -7.96%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted Daré Bioscience's strategic moves towards commercialization and revenue generation through an expanded business strategy and new product launches. However, financial challenges such as a working capital deficit and comprehensive loss, along with regulatory hurdles, present significant concerns.
Q1-2025 Updates
Positive Updates
Expanded Business Strategy
Daré Bioscience announced an expanded business strategy leveraging a dual path strategy to commercialize proprietary formulations via 503B compounding while continuing to seek FDA approval. This strategy aims to accelerate revenue generation and provide a path to profitability.
New Product Launches
Daré is planning to launch three more solutions for women, including two vaginal probiotics in 2025 and a proprietary monthly hormone therapy in 2026, targeting a $4.5 billion market.
Decrease in Operating Expenses
The company's general and administrative expenses decreased by 14%, and R&D expenses decreased by 31% compared to Q1 2024, reflecting cost management efforts.
Strategic Partnerships
Daré is seeking multiple strategic partnerships to provide women access to its evidence-based solutions across multiple channels, including collaborations with telehealth providers and online platforms.
Ovaprene Clinical Progress
The pivotal Phase 3 contraceptive efficacy study for Ovaprene is ongoing, with a Data Safety Monitoring Board interim assessment scheduled for July 2025.
Negative Updates
Working Capital Deficit
Daré ended the first quarter with a working capital deficit of approximately $9.4 million, raising concerns about its financial health.
Comprehensive Loss
The company reported a comprehensive loss of approximately $4.4 million for the quarter.
Regulatory Challenges
Daré received additional input and information requests from the FDA regarding its Sildenafil Cream's psychometric analysis, potentially delaying the Phase 3 study.
Company Guidance
In the recent conference call, Daré Bioscience provided guidance on their strategic direction, highlighting a dual path strategy for product commercialization. They plan to bring four products to market, including their Sildenafil Cream and a monthly hormone therapy, targeting the estimated $4.5 billion hormone therapy market. They aim to record revenue in Q4 2025, capitalizing on a nimble business model that leverages both FDA approval and 503B compounding. Financially, Daré reported a Q1 2025 comprehensive loss of approximately $4.4 million, with general and administrative expenses reduced by 14% and R&D expenses by 31% compared to Q1 2024. They closed the quarter with $10.3 million in cash and a working capital deficit of $9.4 million. The company is actively pursuing strategic partnerships to enhance product access and plans to update stakeholders on these developments, alongside their ongoing pipeline progress, in the coming months.

Daré Bioscience Financial Statement Overview

Summary
Daré Bioscience faces significant financial challenges, with persistent unprofitability, negative equity, and high liabilities indicating financial distress. Despite a recent positive trend in cash flow and revenue growth, the company's long-term sustainability remains questionable without a turnaround in profitability and a more stable balance sheet.
Income Statement
22
Negative
Daré Bioscience has struggled with profitability, as evidenced by consistently negative net income over the years. While there was a notable increase in revenue in 2024, the gross profit margin remains 100% due to revenue equaling gross profit, but this is overshadowed by significant negative EBIT and EBITDA margins, indicating high operational costs. The revenue growth from 2023 to 2024 is positive, which is a good sign, but the company remains unprofitable overall.
Balance Sheet
15
Very Negative
The balance sheet reveals a worrying situation with negative stockholders' equity, indicating financial instability. Additionally, the debt-to-equity ratio is not applicable due to negative equity, and the company is highly leveraged with total liabilities exceeding total assets. The negative equity ratio suggests insolvency risk, which is a significant concern for stakeholders.
Cash Flow
35
Negative
While Daré Bioscience has managed to generate a positive operating cash flow in 2024, indicating some operational efficiency, the free cash flow remains inconsistent over the years. The positive free cash flow to net income ratio in 2024 is a positive indicator, but the historical volatility in cash flows points to potential financial management challenges.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue9.78K2.81M10.00M0.000.00
Gross Profit-14.29M2.77M9.95M-26.41K-43.23K
EBITDA-23.41M-30.90M-31.36M-39.04M-27.36M
Net Income-4.05M-30.16M-30.95M-38.33M-27.40M
Balance Sheet
Total Assets22.10M21.28M43.83M55.81M7.55M
Cash, Cash Equivalents and Short-Term Investments15.70M10.48M34.67M51.67M4.67M
Total Debt1.30M1.40M488.74K270.55K756.84K
Total Liabilities28.11M26.33M32.71M17.05M8.70M
Stockholders Equity-6.01B-5.05M11.11M38.75M-1.15M
Cash Flow
Free Cash Flow4.82M-39.49M-18.15M-28.78M-25.25M
Operating Cash Flow5.39M-38.86M-18.09M-28.76M-25.23M
Investing Cash Flow-573.05K-629.43K-63.07K-14.52K-17.63K
Financing Cash Flow433.83K15.64M1.34M75.85M25.13M

Daré Bioscience Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2.66
Price Trends
50DMA
2.79
Negative
100DMA
2.86
Negative
200DMA
3.12
Negative
Market Momentum
MACD
-0.04
Negative
RSI
50.07
Neutral
STOCH
7.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DARE, the sentiment is Neutral. The current price of 2.66 is above the 20-day moving average (MA) of 2.54, below the 50-day MA of 2.79, and below the 200-day MA of 3.12, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 50.07 is Neutral, neither overbought nor oversold. The STOCH value of 7.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DARE.

Daré Bioscience Risk Analysis

Daré Bioscience disclosed 82 risk factors in its most recent earnings report. Daré Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Daré Bioscience Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$16.84B5.17-7.44%2.89%11.55%-28.15%
50
Neutral
$33.60M-1738.36%-43.55%69.81%
50
Neutral
$23.54M597.53%88.13%92.45%
48
Neutral
$24.16M-66.15%43.03%81.75%
46
Neutral
$29.03M-70.06%146.47%57.85%
41
Neutral
$38.32M-853.05%34.97%
30
Underperform
$49.18M-2880.11%31.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DARE
Daré Bioscience
2.66
-0.94
-26.11%
VYNE
VYNE Therapeutics
1.45
-0.65
-30.95%
CLNN
Clene
3.66
-0.80
-17.94%
PYPD
PolyPid
3.74
0.24
6.86%
GBIO
Generation Bio
4.20
-30.00
-87.72%
NRSN
Neurosense Therapeutics Ltd.
2.05
1.24
153.09%

Daré Bioscience Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Daré Bioscience Announces Positive Phase 3 Trial Results
Positive
Jul 14, 2025

On July 14, 2025, Daré Bioscience announced positive interim results from its Phase 3 clinical trial of Ovaprene®, a hormone-free monthly intravaginal contraceptive. The trial’s data safety monitoring board recommended continuing the study without modification, as no new safety concerns were identified. Approximately 9% of participants experienced pregnancy, aligning with expectations, while 17% discontinued due to vaginal odor. Participants expressed a high likelihood of using Ovaprene if available, highlighting its potential to meet the demand for hormone-free contraceptive options. Bayer has the option to commercialize Ovaprene in the U.S., potentially providing significant financial benefits to Daré.

The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Daré Bioscience Stockholder Meeting Approves Key Proposals
Neutral
Jul 9, 2025

On July 9, 2025, Daré Bioscience reconvened its stockholder meeting initially held on June 12, 2025, which was adjourned due to a lack of quorum. During the meeting, four proposals were voted on, including the election of Class II directors, the ratification of Haskell & White LLP as the independent accounting firm for 2025, approval of executive compensation, and the 2022 Plan Amendment, all of which were passed by the stockholders.

The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Delistings and Listing ChangesRegulatory Filings and Compliance
Daré Bioscience Gains Nasdaq Compliance Extension Approval
Neutral
Jun 25, 2025

On June 24, 2025, Daré Bioscience received approval from the Nasdaq Hearings Panel for its modified plan to regain compliance with Nasdaq Listing Rules, with a conditional continued listing period until August 12, 2025. The company must demonstrate compliance with either the Stockholders’ Equity Rule or the Minimum MVLS Rule by July 31, 2025, or face potential delisting, which could impact its stock market presence and capital-raising capabilities.

The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Business Operations and Strategy
Daré Bioscience Announces Corporate Presentation for Investors
Neutral
Jun 9, 2025

On June 9, 2025, Daré Bioscience, Inc. announced its intention to use a corporate presentation in meetings with securities market participants and others. The presentation will be accessible on the company’s website in the ‘Investors’ section. This move is part of Daré’s strategy to engage with stakeholders and provide transparency about its operations and future plans.

The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 17, 2025